Flexible and scalable nonviral delivery for cGMP cell therapy processing
Closed manufacturing of cell therapies is widely accepted as an effective way to create a safer therapeutic product through reduction of error often associated with traditional manual cell processing techniques. In addition to closing manufacturing systems, the industry is moving toward targeted gene delivery methods such as transfection with CRISPR-Cas9 to achieve both performance and safety enhancements over traditional random integration of vectors.
Download the application note now to learn more about how to transform your current transfection step into one that’s closed, optimized, and scalable, courtesy of Thermo Fisher Scientific.
Your data will be used in accordance with the Thermo Fisher Scientific privacy policy.
Lab Manager needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at anytime.
For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our privacy policy by clicking here.
© 2023 Lab Manager. All rights reserved.